West Pharmaceutical Services (WST) Projected to Post Earnings on Thursday

West Pharmaceutical Services (NYSE:WST) will likely be posting its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect West Pharmaceutical Services to post earnings of $1.83 per share and revenue of $795.6980 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.

West Pharmaceutical Services Stock Down 0.1%

West Pharmaceutical Services stock opened at $248.82 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. The stock has a market capitalization of $17.90 billion, a PE ratio of 36.86, a price-to-earnings-growth ratio of 3.43 and a beta of 1.18. The business has a 50 day simple moving average of $263.66 and a 200-day simple moving average of $261.97. West Pharmaceutical Services has a 12 month low of $187.43 and a 12 month high of $325.20.

West Pharmaceutical Services Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 4th. Investors of record on Wednesday, January 28th were issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend was Wednesday, January 28th. West Pharmaceutical Services’s payout ratio is presently 13.04%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in WST. State Street Corp increased its holdings in shares of West Pharmaceutical Services by 2.1% in the second quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock valued at $715,884,000 after purchasing an additional 68,330 shares during the last quarter. Durable Capital Partners LP grew its holdings in West Pharmaceutical Services by 12.7% in the 3rd quarter. Durable Capital Partners LP now owns 1,172,583 shares of the medical instruments supplier’s stock valued at $307,604,000 after buying an additional 131,935 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of West Pharmaceutical Services by 420.1% in the 3rd quarter. AQR Capital Management LLC now owns 545,879 shares of the medical instruments supplier’s stock worth $142,949,000 after acquiring an additional 440,929 shares during the last quarter. Sei Investments Co. increased its stake in shares of West Pharmaceutical Services by 18.5% in the 3rd quarter. Sei Investments Co. now owns 527,510 shares of the medical instruments supplier’s stock worth $138,381,000 after acquiring an additional 82,259 shares during the last quarter. Finally, Epoch Investment Partners Inc. raised its holdings in shares of West Pharmaceutical Services by 45.6% during the 3rd quarter. Epoch Investment Partners Inc. now owns 525,899 shares of the medical instruments supplier’s stock worth $137,959,000 after acquiring an additional 164,634 shares during the period. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on WST shares. Morgan Stanley began coverage on shares of West Pharmaceutical Services in a research report on Monday, December 1st. They set an “equal weight” rating and a $285.00 price objective for the company. Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Saturday, December 20th. UBS Group raised their price target on shares of West Pharmaceutical Services from $320.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, October 24th. Barclays lifted their price objective on West Pharmaceutical Services from $275.00 to $325.00 and gave the stock an “equal weight” rating in a report on Monday, October 27th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Friday, January 9th. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $330.13.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.